From: Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
1 | 2 | 3 | 4 | |
---|---|---|---|---|
Diagnosis | DM | UCTD | DM | DM |
Symmetrical muscle weakness | P | N | P | Y |
Muscle biopsy | Y | ND | ND | NA |
Elevated muscle enzyme | Y | Y | Y | Y |
EMG | myopathic pattern | myopathic pattern | myopathic pattern | NA |
Dermatologic features | Y (G) | N | P (S) | Y (G, H, S) |
Malignancy | N | Y | N | N |
Interstitial lung disease | N | N | N | N |
Dysphagia | Y | N | N | N |
Raynaud's phenomenon | N | N | N | N |
Arthritis | N | Y | N | N |
CPK (U/L) initial /after Tx (lowest) | 654 167 | 341 239 | 314 | 2414 |
Initial Tx | none | PSL 10 mg | PSL 40 mg | PSL 50 mg |
HCQ 200 mg NSAIDs | HCQ 200 mg | MTX 20 mg/w HCQ 150 mg | ||
Response to Tx | NA | good | good | good |
Other autoantibodies | Ro, Su, U1RNP (Sm) | Mi-2, Su | ||
ELISA (RP) TIF1α | - | - | + | - |
TIF1β | + | + | - | - |
TIF1γ | - | - | - | - |
antigen-capture ELISA | ||||
TIF1α | - | - | - | - |
TIF1β | + | + | weak + | weak + |